Science is our medicine.
VIRIS Detection Systems Inc is an early stage biotechnology company that is developing CRISPR RNA-guided diagnostics.
The near-term focus is on the development of a rapid diagnostic test for SARS-CoV-2 that is affordable and available for daily testing.
"The interfaces of genetic conflict are hot spots for biological and biotechnological innovation. One of these innovations is the evolution of CRISPR-mediated immune systems, for which my former advisor (Jennifer Doudna) and one of her collaborators (Emmanuelle Charpentier) where recently awarded the Nobel Prize in Chemistry for their role in developing this system for applications in genome engineering. But CRISPR systems are diverse, and so are their applications. At VIRIS Detection Systems, we have developed a CRISPR-based diagnostic that is sensitive and specific. The near-term focus is on the development of a rapid diagnostic test for SARS-CoV-2 that is affordable and available for daily testing. However, the platform is versatile and easily repurposed for detection of virtually any virus or other non-viral disease."
Dr. Blake Wiedenheft
VIRIS Founder and CEO
INTERESTED IN JOINING?
VIRIS is looking to add a new member to the team! If you are interested in the opportunity and meet the following qualifications:
Willing to work collaboratively in a lab environment
Possess previous training in molecular biology
Have experience with RT-qPCR
please contact Dr. Wiedenheft (firstname.lastname@example.org) for further details.